Abstract 206P
Background
To compare discriminant ability of risk stratifications for prostate cancer in three authoritative guidelines: National Comprehensive Cancer Network clinical practice guideline (NCCN-g), American Urological Association / American Society for Therapeutic Radiology and Oncology/ Society of Urologic Oncology Guideline(AUA-g) and European Association of Urology- European association of nuclear medicine- European Society for Radiotherapy and Oncology- European Society of Urogenital Radiology- International Society of Geriatric Oncology guideline(EAU-g).
Methods
511916 patients with one primary prostate cancer diagnosed between 2004 and 2016 were identified using the Surveillance, Epidemiology, and End Results (SEER, submitted in) database of the National Cancer Institute. Patients were excluded from analysis if < 18 years of age, not adenocarcinoma, diagnosed at autopsy or death certificate only, with an unknown follow-up, incomplete clinical and demographic information, leaving 287333 patients in this cohort. Patients were categorized as different risk stratifications by three latest guidelines (NCCN-g, AUA-g and EAU-g) respectively. Follow-up endpoint was prostate cancer specific mortality (PCSM), cutoff date was December 31, 2016. Kaplan–Meier analysis, multivariable Cox regression and area under the receiver operating characteristics (ROC) curve (AUC) analyses were performed.
Results
The 287333 patients are all from 2004 to 2015. Median follow-up was 69 months (IQR: 39-104). For the three risk stratification modalities, all 6 risk groups in NCCN-g, 5 risk groups in AUA-g and 5 risk groups in EAU-g independently predicted PCSM. NCCN-g yielded 3.1-fold HR differences between low risk group and intermediate risk group, 14.8-fold HR differences between low risk group and high risk group, 33.0-fold HR differences between low risk group and very high risk group, 56.2-fold HR differences between low risk group and regional group, and 148.9-fold HR differences between low risk group and metastatic group. AUC is 0.8332, 0.8309 and 0.7868 in NCCN-g, AUA-g and EAU-g.
Conclusions
This large population-based analysis confirms the better discriminant properties of the risk stratification method in NCCN guideline.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Peking University First Hospital radiation oncology department.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study
Presenter: Krithika Murali
Session: Poster display session
Resources:
Abstract
155P - Mean Platelet Volume (MPV) is it a new prognostic marker in resectable carcinoma stomach?
Presenter: Girish M. S
Session: Poster display session
Resources:
Abstract
156P - A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Presenter: Zhen Xiang
Session: Poster display session
Resources:
Abstract
157P - Lymph node ratio (LNR) a better prognostic factor after D2 gastrectomy
Presenter: Jitin Yadav
Session: Poster display session
Resources:
Abstract
158P - A clinical significance of preoperative C-reactive protein/albumin ratio in patients with extrahepatic bile duct cancer
Presenter: Kim Jinkook
Session: Poster display session
Resources:
Abstract
159P - The relation between obesity and cancer of gastrointestinal tract in Korea: The data from Statistic Korea between 2001 and 2016
Presenter: Hee Man Kim
Session: Poster display session
Resources:
Abstract
160P - Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
Presenter: Jooyoung Ha
Session: Poster display session
Resources:
Abstract
161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
162P - Hypofractionated radiotherapy for pulmonary metastases from hepatocellular carcinoma: Treatment response and prognostic factors affecting survival
Presenter: In Young Jo
Session: Poster display session
Resources:
Abstract
163P - Excision repair cross-complementation group 1 and 2 (ERCC1/2) Single nucleotide polymorphisms and chemotherapy treatment outcome in Cholangiocarcinoma
Presenter: Thanachai Sanlung
Session: Poster display session
Resources:
Abstract